|View printer-friendly version|
|June 30, 2004 5:09 p.m.|
|Teva Comments On Quinapril Court Ruling|
Jerusalem, Israel, June 30, 2004 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. District Court for the District of New Jersey has issued an opinion following the completion of a trial on Pfizer Inc.'s subsidiary Warner-Lambert U.S. Patent No. 4,743,450, which covers Accupril® Tablets and found the patent to be valid. Teva intends to appeal this decision immediately.